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Abstract 
MicroRNAs (miRNAs) are small non-coding
RNAs  (ncRNAs)  with  important  regulatory
functions.  After  an  initial  phase,  aimed  at
identifying whether a deregulation in miRNA
expression  occurred  between  hematologic
malignancies and their normal counterparts,
currently an increasing number of studies are
focusing  on  the  functional  significance  of
these  aberrancies.  The  identification  of
miRNA targeted genes has cast a new light on
the role of these tiny ncRNAs in human can-
cerogenesis, providing a new rationale to the
observed diagnostic, prognostic and therapeu-
tic implications of miRNA aberrant expression
in human hematologic malignancies.
Introduction
MicroRNAs (miRNAs) are a class of non-
coding RNAs (ncRNAs) with regulatory func-
tions,  involved  in  a  variety  of  biological
processes.
1-6 Initially transcribed by RNA poly-
merase II as long, capped and polyadenylated
precursors (pri-miRNAs),
7,8 miRNAs undergo
a  complex  processing  mechanism.  First,  a
double-stranded  RNA-specific  ribonuclease
called Drosha, in conjunction with its bind-
ing partner DGCR8 (DiGeorge syndrome crit-
ical region gene 8, or Pasha) processes pri-
miRNAs  into  hairpin  RNAs  of  70-100
nucleotides (nt) known as pre-miRNAs.
9 By
means of Exportin 5, pre-miRNA is translo-
cated  from  the  nucleus  to  the  cytoplasm,
where a ribonucleic complex, composed of a
ribonuclease  III  (Dicer),  and  TRBP  (HIV-1
transactivating  response  RNA  binding  pro-
tein) cleaves it in a 18-24 nt duplex. Finally,
the duplex interacts with a large protein com-
plex  called  RISC  (RNA-induced  silencing
complex),  which  includes  proteins  of  the
Argonaute family (Ago1-4 in humans). One
strand of the miRNA duplex remains stably
associated  with  RISC  and  becomes  the
mature miRNA, which guides the RISC com-
plex mainly (but not exclusively) to the 3’-
UTR  (3’-untranslated  region)  of  the  target
mRNAs.  The  final  outcome  of  the  target
mRNA  is  based  upon  the  miRNA:mRNA
degree of base pair complementarity. A per-
fect  base  pair  match  (occurring  mainly  in
plants), leads to mRNA cleavage, whereas an
imperfect complementarity (predominant in
nematodes and mammals) results in transla-
tional silencing of the target, albeit also in
case of imperfect base pairing a reduction of
the target mRNA has been described.
3 A fur-
ther level of complexity in miRNA gene regu-
lation has been recently provided by showing
that miRNAs can also directly up-regulate the
expression of a target gene by binding to its
3’-UTR.
10
The development of high throughput meth-
ods  to  detect  miRNA  expression  in  human
samples,
11,12 has provided invaluable tools to
investigate the role of these ncRNAs in sever-
al  human  pathologies.  It  is  now  generally
accepted  that  miRNAs  are  aberrantly
expressed in almost all human cancers (both
solid  and  hematologic  malignancies),  with
respect  to  the  normal  counterpart.
13-15 This
review will focus on the role of miRNAs in the
pathogenesis of human leukemias and lym-
phomas, highlighting diagnostic, prognostic,
and therapeutic implications of this class of
ncRNAs. Table 1 summarizes the most fre-
quently de-regulated miRNAs in hematologic
malignancies.
miRNAs and leukemias
Leukemia is a malignant disorder of the
blood  or  bone  marrow  characterized  by  an
abnormal proliferation of blood cells. Based
on the stage of differentiation of the malig-
nant  cells,  leukemias  can  be  divided  into
acute and chronic. Acute leukemias are char-
acterized by the rapid increase of immature
blood cells (blood cell progenitors or primi-
tive stem cells with multilineage potential)
and are the most common forms of leukemia
in  children,  while  chronic  leukemias  arise
from  more  mature  cells  during  differentia-
tion  and  occur  more  often  among  adults.
Additionally,  the  diseases  are  subdivided,
according to the origin of the neoplastic cells,
into  lymphoid  leukemias,  concerning  the
lymphoid  pathway  (B  and  T  cells)  and
myeloid  leukemias,  which  involve  the  cells
that normally go on to form red blood cells,
granulocytes, monocytes and platelets. It was
recently reported that the pattern of miRNA
expression varies strongly during the differ-
entiation  of  hematopoietic  stem/progenitor
cells,  playing  a  critical  role  in  events  that
result in hematologic disorders.
16,17
miRNAs in chronic leukemias
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the
most common type of leukemia, characterized
by the slow accumulation in blood, bone mar-
row and lymphatic tissue of small, non-prolif-
erating, mature B lymphocytes, which display
typical  surface  markers  such  as  CD19  and
CD20 in addition to CD5.
18
More than 50% of CLLs are characterized by
hemizygous and/or homozygous deletion of the
genomic region 13q14.
19,20 Calin et al. showed
that a cluster of miRNAs, namely miR-15a/16-
1, is located at chromosome 13q14 and that
these miRNAs, situated within a 30-kb region
of loss in CLL, are both deleted or down-regu-
lated  in  approximately  68%  of  CLL  cases.
21
Among the targets of miR-15a/16-1, was identi-
fied BCL2,
22 an anti-apoptotic protein which is
over-expressed in the majority of CLL B cells,
23
and it is believed to mediate the anti-tumoral
effect of these miRNAs. This finding is sup-
ported  by  the  fact  that  restoration  of
miR15a/16-1 induces apoptosis in MEG-01 cell
line,  derived  from  acute  megakaryocytic
leukemia, pointing out a role for miR15a/16-1
as tumor-suppressor genes (TSGs) in CLL, and
maybe  in  other  malignancies  in  which  this
cluster  is  down-regulated  or  lost.
22,24 Croce’s
group first identified a unique microRNA sig-
nature associated with prognostic factors and
disease progression in CLL,
25 and described a
germ-line mutation in pre-miR-16 sequence,
which causes low levels of microRNA expres-
sion both in vitro and in vivo. This mutation
was  associated  with  deletion  of  the  normal
allele in leukemic cells of 2 CLL patients one of
which with a family history of CLL and breast
cancer.
25 Interestingly, Raveche et al. described
a  point  mutation  in  the  3’-DNA  adjacent  to
Correspondence:  Muller  Fabbri,  Department  of
Molecular  Virology,  Immunology,  and  Medical
Genetics  and  Comprehensive  Cancer  Center,
Ohio State University, Columbus, OH, USA 
E-mail: muller.fabbri@osumc.edu
F.F. and I.V. equally contributed to this work
Acknowledgments:  Dr.  Fabbri  is  recipient  of  a
2009 Kimmel Scholar Award.
Received for publication: 29 April 2009.
Accepted for publication: 5 May 2009.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0)
©Copyright F. Fanini et al., 2009
Licensee PAGEPress, Italy
Hematology Reviews 2009; 1:e8
doi:10.4081/hr.2009.e8[Hematology Reviews 2009; 1:e8] [page 41]
Type of paper
miR-16-1 region, which lets down the expres-
sion  of  this  miRNA  in  the  CLL-prone  New
Zealand black mouse strain model, indicating
that this miRNA functions as an oncosuppres-
sor  in  CLL.
26 By  analyzing  the  result  of
miR15a/16-1 hyperexpression in MEG-01 cells
and in CLL patients both at the transcriptome
and at the proteome level, Calin et al. found
that about 14% of all human genome is direct-
ly or indirectly affected by miR15a/16-1 clus-
ter.
27 Among the genes which are down-regu-
lated by this cluster, there are both oncogenes
(OGs) and TSGs, suggesting that even though
the overall effect of miR15a/16-1 overexpres-
sion  is  anti-tumoral  in  CLL,  it  cannot  be
excluded that other pathways may be impacted
and lead to an overall oncogenic outcome in
other diseases. Further investigations are war-
ranted to verify this hypothesis.
Another 2 miRNAs with a TGS function in
CLL are miR-29b and miR-181b, which direct-
ly  target  TCL1  (T-cell  leukemia/lymphoma
1A),  an  OG  which  co-activates  the  protein
kinase  AKT  (v-akt  murine  thymoma  viral
oncogene homolog 1) and takes part in the
regulation of many pathways involved in cell
survival,  proliferation  and  death.
28 As  evi-
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Table 1. Main aberrantly expressed miRNAs in hematologic malignancies.
miRNA Location Function Targets Malignancy
miR15a/16-1 cluster 13q14.3 TSG/OG BCL2 CLL, HL
miR-29b 7q32.3 (miR-29b-1) TSG TCL1 CLL
1q32.2 (miR-29b-2)
miR-181b 1q31.3 (miR-181b-1) TSG TCL1, TLR4, CARD8, CASP1,  CLL, AML
9q33.3 (miR-181b-2) IL1B, SLC11A1, MSR1, CD64
miR-181a 1q31.3 (miR-181a-1) TSG BCL2, TLR4, CARD8, CASP1,  CLL, AML
9q33.3 (miR-181a-2) IL1B, SLC11A1, MSR1, CD64
miR-155 21q21.3 OG AGTR1, FGF7, ZNF537, CLL, AML (FLT-IDT+), 
ZIC3, IKBKE HL, NHL (BL, ABC-DLBCL)
miR-17-92 cluster 13q31.3 OG/TSG E2F1, PTEN, BIM CML, ALL, HL, NHL 
(B cell lymphomas)
miR-203 14q32.33 TSG ABL1 CML
miR-128a (miR-128-1) 2q21.3 OG/TSG N/A High in ALL vs. AML; 
low in HL EBV+
miR-128b (miR-128-2) 3p22.3 OG/TSG N/A High in ALL vs. AML;
low in HL EBV+
let-7b 22q13.31 OG/TSG RAS High in AML vs. ALL
miR-223 Xq12 OG N/A High in AML vs. ALL
miR-204 9q21.11 TSG HOXA10, MEIS1 AML (NPM1 mut)
miR-34b 11q23.1 TSG CREB AML
miR-9 1q22 (miR-9-1) OG PRDM1/Blimp-1 HL
5q14.3 (miR-9-2)
15q26.1 (miR-9-3)
let-7a 9q22.32 (let-7a-1) OG/TSG RAS, PRDM1/Blimp-1 HL
11q24.1 (let-7a-2)
22q13.31 (let-7a-3)
miR-96 7q32.2 TSG N/A Low in HL EBV+
miR-21 17q23.1 OG PTEN, PDCD4 HL, NHL (ABC-DLBCL)
miR-24 9q22.32 (miR-24-1) OG N/A HL
19p13.12 (miR-24.2)
miR-150 19q13.33 TSG N/A HL
miR-221 Xp11.3 OG N/A NHL (ABC-DLBCL)
miR-143 5q33.1 TSG ERK5 NHL (B-cell lymphomas)
miR-145 5q33.1 TSG ERK5 NHL (B-cell lymphomas)
OG: oncogene; TSG: tumor suppressor gene; BCL2: B-cell CLL/lymphoma 2; TCL1: T-cell leukemia/lymphoma 1A; TLR4: toll-like receptor 4; CARD8: caspase recruitment domain family, member 8;
CASP1: caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase); IL1B: interleukin 1, beta; SLC11A1: solute carrier family 11 (proton-coupled divalent metal ion trans-
porters), member 1; MSR1: macrophage scavenger receptor 1; CD64: Fc fragment of IgG, high affinity 1a, receptor; AGTR1: angiotensin II receptor, type 1; FGF7: fibroblast growth factor 7 (ker-
atinocyte growth factor); ZNF537: teashirt zinc finger homeobox 3; ZIC3: Zic family member 3 (odd-paired homolog, Drosophila); IKBKE: inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase epsilon; E2F1: E2F transcription factor 1; PTEN: phosphatase and tensin homolog; BIM: BCL2-like 11 (apoptosis facilitator); ABL1: c-abl oncogene 1, receptor tyrosine kinase; RAS: rat
sarcoma virus; HOXA10: homeobox A10; MEIS1: myeloid ecotropic viral integration site 1 homolog; CREB: cAMP responsive element binding protein 1; PRDM1/Blimp1: PR domain containing 1, with
ZNF domain; PDCD4: programmed cell death 4 (neoplastic transformation inhibitor); ERK5: mitogen-activated protein kinase 7; N/A: not available; CLL: chronic lymphocytic leukemia; ALL: acute lym-
phocytic leukemia; CML: chronic myeloid leukemia; AML: acute myeloid leukemia; HL: Hodgkin’s lymphoma; NHL: Non-Hodgkin’s lymphoma; BL: Burkitt’s lymphoma; DLBCL: diffuse large B-cell lym-
phoma; ABC: activated B-cell phenotype; EBV+: Epstein-Barr virus positive; FLT-IDT+: fms-related tyrosine kinase 3 gene internal tandem dupication; NPM1 mut: nuclephosmin-1 mutation.denced by transgenic mice models, TCL1 is a
marker of aggressive CLL and its high levels
are associated with high levels of ZAP-70 (70
kD zeta chain-associated protein kinase) and
unmutated IgVH status which are both mark-
ers of poor prognosis in CLL.
29,30 In a recent
study, a correlation between low levels of miR-
29c and poor prognosis was observed in CLL
patients. In a 110 patient cohort with a medi-
an  follow-up  of  72  months,  the  authors
showed  for  the  first  time  that  a  specific
threshold of expression for miR-29c and miR-
223 can predict treatment-free survival (TFS)
and  overall  survival  (OS).
31 While  miR-181b
targets TCL1, miR-181a directly targets BCL2,
together  with  miR-15a/16-1  cluster,
22,32 sug-
gesting a central role of the miR-181 family
members in the pathogenesis of CLL. A study
aimed at investigating a possible correlation
between the two groups of miRNAs is war-
ranted.
Finally, miR-155 was showed to be up-regu-
lated in CLL versus normal CD19
+ B cells,
33 and
the role of this miRNA will be analyzed more
extensively in the paragraph of lymphomas.
Chronic myeloid leukemia
Using  microarray  analysis  (miCHIP)  and
miRNA-specific  quantitative  real-time
reverse transcriptase-polymerase chain reac-
tion (miR-qRT-PCR), Venturini et al. reported
BCR-ABL1-  and  c-MYC-dependent  transacti-
vation  of  miR-17-92  cluster,  a  polycistronic
gene located in human chromosome 13 ORF
25 (C13orf25) at 13q31-q32 and composed of
7  mature  miRNAs  namely  miR-17–5p,  miR-
17–3p, miR-18a, miR-19a, miR-20a, miR-19b
and miR-92–1, in chronic myeloid leukemia
cell  lines.
34 BCR-ABL1-MYC  pathway  can
induce this transactivation in early chronic
phase but not in blast crisis CML CD34
+ cells,
suggesting a role for miR-17-92 cluster in the
pathogenesis  of  chronic  myeloid  leukemia
(CML).
34
Recently, Bueno et al. identified a fragile
chromosomal  region  lost  in  specific
hematopoietic malignancies, which encodes
about 12% of all genomic miRNAs, including
miR-203 which directly targets ABL1.
35 In a T-
cell lymphoma model, both genetic and epige-
netic  mechanisms  inactivated  this  miRNA.
Specifically  the  miR-203  promoter  resulted
hypermethylated in chromosome Philadelphia
positive (Ph+) tumors, including B-cell ALLs,
primary  CMLs  and  cultured  CML  cell  lines
while  no  methylation  was  observed  in
hematopoietic tumors that do not carry ABL1
alterations.  Re-expression  of  miR-203
reduces ABL1 and BCR-ABL1 fusion protein
levels and inhibits tumor cell proliferation in
an ABL1-dependent manner, putting forward
the role of miR-203 as a TSG whose re-expres-
sion might have therapeutic benefits in spe-
cific  hematopoietic  malignancies.
35 It  would
be  intriguing  to  investigate  whether  the
silencing effect of miR-203 on ABL1 can have
any  indirect  or  modulatory  consequence  on
the miR-17-92 cluster.
miRNAs in acute leukemias
Acute lymphocytic leukemia
Acute lymphocytic leukemia (ALL) is one of
the most common malignancies observed in
the pediatric age and it represents about the
80% of cases of acute leukemia in children. It
arises  from  the  clonal  proliferation  of  lym-
phoid progenitors in the bone marrow whose
consequence is the occurrence of several dif-
ferent cytopenias in the peripheral blood asso-
ciated with the appearance of peripheral blast
cells. In 2007, Zanette et al. analyzed miRNA
expression profiles in 7 ALL samples and 6
normal  CD19
+ samples  in  order  to  compare
them. They first reported the involvement of
miR-128b,  miR-204,  miR-218,  miR-331  and
miR-181b-1  in  hematologic  malignancies,
with  miR-128b  as  the  most  represented
miRNA in ALL. In their analysis also the miR-
17-92  cluster  resulted  up-regulated  in  all  7
samples.
36 The  nucleotide  sequences  and
organization  of  this  cluster  is  highly  con-
served in vertebrates,
37 and its expression is
tightly regulated during B-cell development. A
role of miR-17-92 cluster to promote survival
of  early  B-cell  progenitors  in  a  cell-
autonomous manner, and control cell survival
during  the  pro-B  to  pre-B  transition  was
recently suggested by Ventura et al. They pro-
posed that in human B-cell lymphomas miR-
17-92 overexpression is induced at the pro-B
to pre-B transition where it acts to silence the
expression of the pro-apoptotic protein Bim,
leading to an abnormal survival of pro-B lym-
phocytes.
38 In another study, Mi et al. tried to
understand the distinct mechanisms in leuke-
mogenesis between ALL and AML and to iden-
tify markers for diagnosis and treatment, per-
forming a large-scale genomewide microRNA
expression profiling assay. They identified 27
miRNAs  that  are  differentially  expressed
between ALL and AML. Among them, miR-128a
and miR-128b which are up-regulated in ALL
vs. AML, and let-7b, miR-223 which are down-
regulated in ALL vs. AML, can lead to a differ-
ential diagnosis between the acute leukemias,
with an accuracy of 98%. Furthermore, they
found that overexpression of miR-128 in ALL
was at least partly associated with its promot-
er hypomethylation and not with an amplifica-
tion  of  its  genomic  locus,  suggesting  an
important role of epigenetics in the regulation
of  the  expression  of  miRNAs  in  acute
leukemias.
39 The leukemogenic mechanism of
miR-128b remains still poorly understood.
Acute myeloid leukemia
Recently, several works have analyzed which
aberrancies in the miRNome (defined as the
full spectrum of miRNAs expressed in a partic-
ular cell type) occur in acute myeloid leukemia
(AML) patients. Garzon et al. investigated 240
AML  patient  samples  to  determine  whether
miRNAs  are  associated  with  cytogenetic
abnormalities  and  clinical  features  in  acute
myeloid leukemia. For this purpose, they eval-
uated miRNA expression of CD34
+ cells and
122  untreated  adult  AML  cases  using  a
microarray  platform.  They  identified  some
miRNAs  differentially  expressed  between
CD34
+ normal  cells  and  the  AML  samples
whose expression was also closely associated
to selected cytogenetic and molecular abnor-
malities, such as t(11q23), isolated trisomy 8,
and FLT3-ITD (fms like tyrosine kinase 3 in
tandem duplication) mutations. Furthermore,
they found that patients with high expression
of miR-191 and miR-199a were associated with
worse overall and event-free survival than AML
patients  with  low  expression,  suggesting  a
possible prognostic role for these 2 miRNAs.
40
In  normal  karyotype,  AML  nucleophosmin-1
(NPM1) and FLT3-ITD mutations are frequent-
ly found. In NPM1 mutated cases up-regulation
of miR-10a, -10b, several let-7 and miR-29 fam-
ily  members,  as  well  as  down-regulation  of
miR-204 were observed. Intriguingly, miR-204
targets  the  HOX  genes  HOXA10  and  MEIS1,
suggesting  that  the  HOX  up-regulation
observed in NPMc+ AML (cytoplasmic nucle-
ophosmin) may be due at least in part to loss
of HOX regulator-miRNAs.
41 FLT3-ITD
+ samples
showed up-regulation of miR-155 which was
demonstrated to be strongly but independently
associated with FLT3-ITD mutations.
41 In a ret-
rospective  study  conducted  on  samples  of
leukemia cells from patients who had cytoge-
netically normal AML and high-risk molecular
features such as FLT3–ITD
+, a wild-type NPM1
or both, Marcucci et al. found that expression
levels of microRNA-181 family were inversely
correlated with those of predicted target genes
encoding proteins which take part in pathways
controlled  by  toll-like  receptors  and  inter-
leukin-1β
42 (Table 1). In another  study, Fazi et
al. analyzed patient’s primary leukemia blasts,
and  demonstrated  that  those  carrying  the
t(8;21),  which  generates  the  most  common
acute myeloid leukemia-associated fusion pro-
tein AML1/ETO, exhibited low levels of miRNA-
223, a regulator of myelopoiesis. They showed
that miR-223 is a direct transcriptional target
of  AML1/ETO  which  causes  heterochromatic
silencing  of  this  miRNA  by  recruiting  chro-
matin remodeling enzymes at an AML1-bind-
ing site on the pre-miR-223 gene. Ectopic miR-
223  expression,  RNA  interference  against
AML1/ETO, or demethylation enhance miR-223
levels and restore cell differentiation. These
findings confirm a central role of miR-223 in
Article
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essential  function  of  this  miRNA  in  normal
myeloid ontogeny.
43 Recently, a possible mech-
anism for CREB (cyclic AMP-responsive ele-
ment  binding  protein)  overexpression  in
leukemia mediated by mir-34b has been pro-
vided.  Using  real-time  quantitative  PCR,
Pigazzi et al. discovered that miR-34b was sig-
nificantly less expressed in myeloid cell lines
which are known to have high CREB protein
level.  When  exogenous  miR-34b  expression
was  induced  in  vitro the  CREB  levels
decreased as a consequence of a direct interac-
tion between miR-34b and the CREB 3’-UTR.
Moreover, mir-34b restored expression caused
alteration in CREB target gene expression and
cell cycle abnormalities suggesting a role as
potential  TSG.  In  leukemia  cell  lines,  they
showed  that  miR-34b/miR-34c  promoter  was
methylated  and  this  epigenetic  regulation
should  control  the  observed  mir-34b  expres-
sion  levels  to  preserve  Creb  protein  overex-
pression.  The  inverse  relationship  between
miR-34b and CREB was also supported in vivo
in a cohort of 78 pediatric patients.
44
miRNAs and lymphomas
MiRNAs are involved in the pathogenesis of
both  Hodgkin  and  non-Hodgkin  lymphomas.
There are many studies that describe the role
of miRNAs in these two groups of lymphomas. 
Hodgkin lymphoma
Nie et al. showed that miR-9 and let-7a tar-
get  PRDM1/Blimp-1  in  Hodgkin  lymphomas
cell lines. In fact, the levels of miR-9 and let-7a
inversely  correlated  with  PRDM1/Blimp-1
expression in Hodgkin Lymphoma (HL) cells.
Similar  to  their  in  vitro counterparts,  the
majority of cells in primary HL cases showed
weak  or  no  PRDM1/Blimp-1  expression.
45
Navarro  et  al.,  analyzed  the  expression  of
miRNAs  in  49  HL  patients  and  10  reactive
lymph nodes. They identified 25 miRNAs dis-
criminating HL from reactive lymph nodes and
36 miRNAs differentially expressed the nodu-
lar  sclerosis  and  mixed  cellularity  subtype.
46
The obtained results, validated in a set of dif-
ferent  cell  lines,  showed  that  miR-96,  miR-
128a, and miR-128b were selectively down-reg-
ulated in HL with EBV. Moreover, only one of
the miRNAs differentially expressed in EBV
+
cases was enclosed in the 25 miRNA that dis-
tinguish HL from reactive lymph nodes, lead-
ing  to  the  intriguing  conclusion  that  EBV
might not be a relevant event in HL pathogen-
esis.
46 Gibcus el al. described a specific miRNA
expression profile in HL cell lines. By compar-
ing HL with a panel of B-cell non-Hodgkin lym-
phomas, they identified a signature of HL-spe-
cific miRNAs, which included miR-17-92 clus-
ter  members,  miR-16,  miR-21,  miR-24,  and
miR-155. A significant down-regulation in HL
was observed for miR-150 whereas an impor-
tant up-regulation in HL was shown for miR-
155.
47 Moreover, the Authors identified AGTR1,
FGF7, ZNF537, ZIC3, and IKBKE as true miR-
155  target  genes  in  HL.
47 Interestingly,  high
levels of miR-155 have also been observed in
the  germinal  center  during  normal  lym-
phopoiesis.
48 Since  HL  has  its  origin  in  the
lymph-nodal  germinal  center,  the  hypothesis
that overexpression of miR-155 is a result of
an aberrant lymphocytic block of differentia-
tion in the germinal center is compelling. 
Non-Hodgkin lymphomas
Up-regulation  of  miR-155  has  also  been
described in Non Hodgkin lymphomas (NHLs),
as well as in several other solid and hematolog-
ic  malignancies.  The  first  hint  of  miR-155
involvement in lymphomagenesis derived from
the observation that the final part of the B-cell
integration  cluster  (BIC)  non-coding  RNA
(ncRNA),  where  miR-155  is  positioned,
increases MYC-mediated lymphomagenesis in
a chicken experimental model.
49 Kluiver et al.
showed that the expression of both miR-155
and its host gene is induced by protein kinase
C  and  NF-kB  in  several  cell  lines,  except
Ramos,  a  Burkitt’s  lymphoma  cell  line,  in
which, for yet unclear reasons, the overexpres-
sion of BIC is not accompanied by up-regula-
tion  of  miR-155.
50 Transgenic  and  knockout
(KO) miR-155 mice models have significantly
contributed  to  clarify  the  function  of  this
ncRNA.  In  Costinean’s  transgenic  mouse
model, miR-155 overexpression caused a poly-
clonal pre-leukemic pre-B-cell proliferation fol-
lowed by full blown B-cell malignancy, provid-
ing in vivo evidence of this miRNA involve-
ment  in  the  pathogenesis  of  hematologic
malignancies.
51 Conversely,  KO  mice  models
showed  impairment  of  cytokine  production
toward  TH2  lymphocyte  differentiation,  and
compromised  function  of  dendritic  cells,
52,53
confirming the data of Tili et al., who showed a
central  role  of  miR-155  in  regulating  the
immune response.
54
In a subgroup of NHLs, the diffuse large B-
cell lymphomas (DLBCL), miR155 up-regula-
tion occurs in the activated B-cell phenotype
(ABC-DLBCL)  with  respect  to  the  germinal
center B-cell-like phenotype (GCB-DLBCL).
55,56
Since  ABC-DLBCL  and  GCB-DLBCL  have  5-
year survival rates of 30% and 59%, respective-
ly,
57 miR-155  expression  harbors  prognostic
implications. In ABC-DLBCL also high levels of
miR-21 and miR-221 were described, suggest-
ing a 3 miRNA-signature specific of the histo-
type of DLBCL with severe prognosis.
56 Roehle
et al. compared the miRNome of DLBCL, follic-
ular lymphomas and reactive lymph nodes. In
particular, they found that 4 miRNAs (namely
miR-330, -17-5p, -106a and -210) can discrimi-
nate DLBCL, follicular lymphomas and reactive
lymph nodes with an accuracy of 98%.
58 It is
compelling  that  among  the  de-regulated
miRNAs of Roehle’s work, there are miR-17-5p
and  miR-106a,  members  of  two  paralogous
clusters with a documented role as oncogenes
in several human malignancies.
37
Located  at  13q31-32,  miR-17-92  cluster  is
frequently amplified in malignant B-cell lym-
phomas, and is over-expressed in 65% of B-cell
lymphoma patients.
59 Overexpression of miR-
17-92 in murine multipotent progenitor cells
(MPPs)  of  MYC-transgenic  mice  caused  an
increased lymphomagenesis.
59 Xiao et al. gen-
erated mice with high miR-17-92 lymphocytic
expression and described a higher rate of lym-
phoproliferative disorders, autoimmunity and
premature death.
60 These pathological charac-
teristics were induced by down-regulation of
the  oncosuppressor  genes  PTEN  and  BIM.
60
O’Donnell et al. showed that c-MYC activates 2
members of the cluster (namely miR-17-5p and
miR-20a), which directly target E2F1, a c-MYC
transactivated transcription factor promoting
cell-cycle progression.
61 In summary, by direct-
ly transactivating E2F1 and indirectly (through
miR-17-92 cluster) repressing its translation,
c-MYC functions as a key-regulator of cell-cycle
progression.  Recently,  Li  et  al. investigated
genome-wide  miRNA  expression  and  copy
number in 86 DLBCLs (59 primary tumors and
27  cell  lines),  and  identified  a  collection  of
miRNAs that robustly segregated DLBCLs into
three subgroups not related to the cell-of-ori-
gin classification, extent of T-cell infiltrate and
tumor  site.
62 In  particular,  the  three  newly
identified  subsets  of  DLBCLs  had  different
prognosis  and  showed  a  markedly  different
MYC transcriptional activity, which was corre-
lated  with  the  dominance  of  MYC-regulated
miRNAs  in  their  expression  signatures.
62
Finally, also miR-143 and miR-145 expression
is reduced in B-cell malignancies.
63 In Burkitt’s
lymphoma Raji cell line, restoration of these
two miRNAs caused a dose-dependent growth
inhibitory effect linked to a down-regulation of
Erk5, a MAP kinase directly targeted by miR-
143 and miR145.
63
Conclusions
There is increasing evidence in literature to
support a central role for miRNAs in the patho-
genesis  of  hematologic  malignancies.
Aberrancies  in  miRNA  expression  lead  to
abnormal gene regulation and, ultimately, to a
severe  alteration  in  proteic  effectors  with
oncogenetic  and/or  oncosuppressor  function.
From the initial contribution of high through-
put techniques, which allowed  the identifica-
tion  of  the  de-regulated  miRNAs,  currently
many efforts are being made to understand the
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expression. For several hematologic malignan-
cies, a clear diagnostic and prognostic role of
miRNA de-regulation has been demonstrated.
The identification of miRNA targeted mRNAs
is  clarifying  which  oncogenic  pathways  are
affected  by  the  leukemic/lymphomatous
miRNome.  This  knowledge  represents  the
essential  background  to  the  development  of
new  miRNA-based  therapeutic  approaches,
which combine the advantage of a physiologic
molecule (such as an miRNA-derived drug), to
the possibility of targeting with a single mole-
cule several members of the same and/or of
several  aberrantly  activated  pathways  in  the
malignancy.  More  studies  are  warranted  to
define how big is the impact of these tiny RNA
molecules in human cancerogenesis. However,
there is no doubt that these ncRNAs play a role
in  hematologic  malignancies.  Decoding  this
role has diagnostic, prognostic and therapeutic
implications of the utmost importance.
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